In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Defense Of “Me-Too” Drugs: Is Primary Care Losing Out To Rare Disease R&D?

Executive Summary

Regulatory and financial incentives have sparked major investment in orphan drug development, but now some stakeholders are questioning whether the focus on orphans is orphaning another market: primary care conditions that are still not adequately treated. Are incentives needed?


Related Content

Focusing R&D In The Age Of Speed: An Interview With Bristol-Myers Squibb CSO Francis Cuss
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
More Me-Too Drugs Please, FDA’s Jenkins Asks Industry
Lessons Learned: How Avandia is Changing the Way FDA Does Business
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts